ES2097703B1 - Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. - Google Patents
Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.Info
- Publication number
- ES2097703B1 ES2097703B1 ES09500739A ES9500739A ES2097703B1 ES 2097703 B1 ES2097703 B1 ES 2097703B1 ES 09500739 A ES09500739 A ES 09500739A ES 9500739 A ES9500739 A ES 9500739A ES 2097703 B1 ES2097703 B1 ES 2097703B1
- Authority
- ES
- Spain
- Prior art keywords
- eburnamenine
- alkaloids
- nucleus
- alcaloids
- brain activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VKTOXAGUZWAECL-RBUKOAKNSA-N eburnamenine Chemical class C1=CC=C2C(CCN3CCC4)=C5[C@H]3[C@@]4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-RBUKOAKNSA-N 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 229930013930 alkaloid Natural products 0.000 title abstract 3
- 230000007177 brain activity Effects 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 244000299461 Theobroma cacao Species 0.000 abstract 2
- 235000009470 Theobroma cacao Nutrition 0.000 abstract 2
- VKTOXAGUZWAECL-OALUTQOASA-N eburnamenine Natural products C1=CC=C2C(CCN3CCC4)=C5[C@H]3[C@]4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-OALUTQOASA-N 0.000 abstract 2
- VKTOXAGUZWAECL-UHFFFAOYSA-N trans-eburnamenine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-UHFFFAOYSA-N 0.000 abstract 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 241001255907 Tonica Species 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000015961 tonic Nutrition 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/56—Cocoa products, e.g. chocolate; Substitutes therefor making liquid products, e.g. for making chocolate milk drinks and the products for their preparation, pastes for spreading, milk crumb
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
- A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/14—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing fruits, nuts, e.g. almonds, seeds, plants, plant extracts, essential oils
Abstract
UNA NUEVA COMPOSICION ESTIMULANTE DE LA ACTIVIDAD CEREBRAL BASADA EN ALCALOIDES DE NUCLEO DE EBURNAMENINA, Y SUS METODOS DE PREPARACION. LA PRESENTE INVENCION SE BASA EN EL DESCUBRIMIENTO DE LA POTENTE ACCION QUE PRESENTAN CIERTOS ALCALOIDES DE NUCLEO DE EBURNAMENINA CUANDO SE ADMINISTRAN CONJUNTAMENTE CON COMPUESTOS DE ESTRUCTURA DE XANTINA. SE OBTIENE UNA POTENTE ACCION SINERGICA EN LA CAPACIDAD COGNOSCITIVA Y POR TANTO, LA ACTIVIDAD CEREBRAL SE VE REFORZADA EN GENERAL A CORTO Y LARGO PLAZO TRAS LA ADMINISTRACION ORAL DE LA COMPOSICION QUE SE PATENTA. LA COMPOSICION QUE SE PATENTA CONTIENE CANTIDADES COMPRENDIDAS ENTRE 0,5 Y 10YMG DE ALCALOIDES O EXTRACTO DE ALCALOIDES DEL TIPO EBURNAMENINA POR CADA 100YML DE BEBIDA DE COLA, LIMON, CACAO, GINSENG, AGUA TONICA, CAFE, O CUALQUIER OTRA BEBIDA A PARTIR DE EXTRACTOS, Y CANTIDADES COMPRENDIDAS ENTRE 0,5 Y 30YMG DE ALCALOIDES O EXTRACTO DE ALCALOIDES DEL TIPO EBURNAMENINA POR CADA 5-20YG DE EXTRACTO SECO, SEMISECO O HUMEDO DE CAFE, COLA, CACAO,TE, GINSENG DE TONICA O CUALQUIER OTRO EXTRACTO PARA BEBIDA.
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09500739A ES2097703B1 (es) | 1995-04-12 | 1995-04-12 | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. |
AT96909178T ATE306268T1 (de) | 1995-04-12 | 1996-04-10 | Zusammensetzung enthaltend vinpocetin-citrat und einen xanthin-enthaltenden pflanzenextrakt zur stimulierung der gerhirnaktivität |
EA199600105A EA000189B1 (ru) | 1995-04-12 | 1996-04-10 | Композиция на основе алкалоидов эбурнаменинового типа, стимулирующая церебральную активность |
MX9606217A MX9606217A (es) | 1995-04-12 | 1996-04-10 | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. |
EP96909178A EP0760240B1 (en) | 1995-04-12 | 1996-04-10 | Composition for stimulating the cerebral activity comprising vinpocetine citrate and a plant extract comprising xanthines |
DE69635257T DE69635257D1 (de) | 1995-04-12 | 1996-04-10 | Zusammensetzung enthaltend Vinpocetin-Citrat und einen Xanthin-enthaltenden Pflanzenextrakt zur Stimulierung der Gerhirnaktivität |
CA002192438A CA2192438C (en) | 1995-04-12 | 1996-04-10 | Novel composition stimulating the cerebral activity and based on alkaloids having an eburnamenine nucleus, and preparation methods |
HU9603272A HU225463B1 (en) | 1995-04-12 | 1996-04-10 | An oral composition enhancing brain's activity |
PCT/ES1996/000082 WO1996032113A1 (es) | 1995-04-12 | 1996-04-10 | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preraracion |
BR9606302A BR9606302A (pt) | 1995-04-12 | 1996-04-10 | Composição estimulante da atividade cerebral para uso oral |
CNB961905913A CN1161122C (zh) | 1995-04-12 | 1996-04-10 | 基于具有象牙烯宁核的生物碱的刺激大脑活动的新组合物及其制备方法 |
NZ304889A NZ304889A (en) | 1995-04-12 | 1996-04-10 | Oral composition, which stimulates cerebral activity, containing alkaloids of the eburnamenine type and xanthine bases containing plant extracts |
AU52769/96A AU719877B2 (en) | 1995-04-12 | 1996-04-10 | A new composition which stimulates cerebral activity, based upon alkaloids with an eburnamenine nucleus, and methods for their preparation |
PL96317647A PL185056B1 (pl) | 1995-04-12 | 1996-04-10 | Kompozycja do podawania doustnego |
JP8530733A JPH10501558A (ja) | 1995-04-12 | 1996-04-10 | エブルナメニン核のアルカロイドを主原料とする大脳活動を刺激する新しい組成物及びその調製法 |
NO19965303A NO313536B1 (no) | 1995-04-12 | 1996-12-11 | Nytt preparat som stimulerer den cerebrale aktivitet og basert pa alkaloider som har en eburnameninkjerne |
US09/654,332 US6290994B1 (en) | 1995-04-12 | 2000-09-01 | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity |
JP2007247938A JP2008056681A (ja) | 1995-04-12 | 2007-09-25 | エブルナメニン核のアルカロイドを主原料とする大脳活動を刺激する新しい組成物及びその調製法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09500739A ES2097703B1 (es) | 1995-04-12 | 1995-04-12 | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2097703A1 ES2097703A1 (es) | 1997-04-01 |
ES2097703B1 true ES2097703B1 (es) | 1997-12-01 |
Family
ID=8290094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09500739A Expired - Fee Related ES2097703B1 (es) | 1995-04-12 | 1995-04-12 | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6290994B1 (es) |
EP (1) | EP0760240B1 (es) |
JP (2) | JPH10501558A (es) |
CN (1) | CN1161122C (es) |
AT (1) | ATE306268T1 (es) |
AU (1) | AU719877B2 (es) |
BR (1) | BR9606302A (es) |
CA (1) | CA2192438C (es) |
DE (1) | DE69635257D1 (es) |
EA (1) | EA000189B1 (es) |
ES (1) | ES2097703B1 (es) |
HU (1) | HU225463B1 (es) |
MX (1) | MX9606217A (es) |
NO (1) | NO313536B1 (es) |
NZ (1) | NZ304889A (es) |
PL (1) | PL185056B1 (es) |
WO (1) | WO1996032113A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2115561B1 (es) * | 1996-12-10 | 1999-02-16 | L B N Lab S L | Composicion energetica para uso alimentario. |
US6228418B1 (en) * | 1999-04-07 | 2001-05-08 | Cyvex Nutrition | Vegetarian pet treat |
PT1355669E (pt) * | 2000-08-10 | 2012-01-02 | Cold Spring Harbor Lab | Treino cognitivo aumentado |
US8153646B2 (en) * | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
US7207263B2 (en) * | 2003-01-21 | 2007-04-24 | Frito-Lay North America, Inc. | Single mold form fryer with product centering elements |
WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
EP1744732A4 (en) * | 2004-05-07 | 2009-08-26 | Thermo Formulations Ltd | NUTRITIONAL COMPOSITION FOR INCREASING CREATINE IN A SKELETON MUSCLE |
DK2258376T3 (en) | 2004-07-27 | 2019-04-15 | Gilead Sciences Inc | Phosphonate analogues of HIV inhibitor compounds |
US20060051461A1 (en) * | 2004-09-03 | 2006-03-09 | Jose Antonio | Nutrified coffee compositions |
US20080044522A1 (en) * | 2004-09-03 | 2008-02-21 | Jose Antonio | Nutrified coffee compositions |
US20080003278A1 (en) * | 2006-06-28 | 2008-01-03 | Fernando Calvo Mondelo | Food products and dietary supplements for improving mental performance |
JP2008017734A (ja) * | 2006-07-11 | 2008-01-31 | Memory Secret Inc | 精神的機能を改善するための栄養補助及び栄養摂取食品用の口経投与組成物 |
US8046976B2 (en) | 2006-07-25 | 2011-11-01 | The Coca-Cola Company | Devices and methods for packaging beverages |
EP2307435B1 (en) * | 2008-07-08 | 2012-06-13 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
BRPI0922759A2 (pt) * | 2008-12-01 | 2016-01-05 | Targacept Inc | síntese e novas formas de sal de (r)-5((e)-2-(pirrolidin-3-ilvinil)pirimidina |
ATE553657T1 (de) * | 2008-12-29 | 2012-05-15 | Unilever Nv | GEFRORENE SÜßWARENPRODUKTE, DIE THEOBROMIN UND KOFFEIN ENTHALTEN |
US11806352B2 (en) | 2010-05-19 | 2023-11-07 | Upfield Europe B.V. | Theobromine for increasing HDL-cholesterol |
CN104382846A (zh) * | 2014-10-27 | 2015-03-04 | 威海爱威制药有限公司 | 长春西汀葡萄糖注射液及其制备方法 |
EP3328385B1 (en) * | 2015-08-01 | 2020-07-08 | Sun Pharmaceutical Industries Ltd | Dosage form of vinca alkaloid drug |
CN105153147A (zh) * | 2015-08-04 | 2015-12-16 | 江苏正大清江制药有限公司 | 一种长春西汀与磷酸形成的盐的晶型及制备方法 |
JP6977236B2 (ja) * | 2016-08-04 | 2021-12-08 | 哈薬集団制薬総厂Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory | ジアザ−ベンゾフルオランテン化合物の塩の型及び結晶形 |
IT201700025286A1 (it) * | 2017-03-07 | 2018-09-07 | Linnea Sa | Forme cristalline di vinpocetina cloridrato |
ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2193586A1 (en) * | 1972-07-31 | 1974-02-22 | Centre Etd Ind Pharma | Vincamine dioctyl sulphosuccinate for medical use - for humans and animals as a cerebral and coronary vasodilator, with no bitter taste |
FR2193587A1 (en) * | 1972-07-31 | 1974-02-22 | Centre Etd Ind Pharma | Vincamine lauryl sulphate compsns - for humans and animals, as a cerebral and coronary vasodilator, without bitter taste |
FR2255890B1 (es) | 1973-12-28 | 1978-01-13 | Centre Etd Ind Pharma | |
ES430063A1 (es) * | 1974-09-14 | 1976-10-01 | Corbera Gubern | Procedimiento para la obtencion de una sal del acido alfa- cetoglutarico. |
FR2319362A1 (fr) * | 1975-07-31 | 1977-02-25 | Parcor | Medicament a base de substances possedant le squelette de l'eburnane |
DE2559384A1 (de) | 1975-12-31 | 1977-07-14 | Josef Dipl Chem Dr Rer N Klosa | Coffein-kombination |
ATE732T1 (de) | 1978-10-18 | 1982-03-15 | Tate & Lyle Patent Holdings Limited | Verfahren zur herstellung von 2-chlor-2-deoxy-sacchariden und einige 2-chlor-2-deoxy-saccharide. |
US4362730A (en) * | 1980-08-25 | 1982-12-07 | Heinrich Mack Nachf. Chem-Pharm. Fabrik | Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein |
EP0154756B2 (fr) * | 1984-02-29 | 1996-10-23 | Covex (S.A.) | Citrate de vinpocetine et son procédé de préparation |
ES8505677A1 (es) * | 1984-05-10 | 1985-06-16 | Covex Sa | Procedimiento para la preparacion del citrato de la (+) vinpocetina |
US4966893A (en) | 1989-01-13 | 1990-10-30 | Pang Peter K T | Method for treatment of senile dementia |
IT1236649B (it) | 1989-11-03 | 1993-03-25 | Nuovo Pignone Spa | Sistema perfezionato di azionamento a nastro della pinza portatrama per un telaio tessile senza navetta. |
US5571441A (en) | 1994-11-01 | 1996-11-05 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
-
1995
- 1995-04-12 ES ES09500739A patent/ES2097703B1/es not_active Expired - Fee Related
-
1996
- 1996-04-10 AT AT96909178T patent/ATE306268T1/de not_active IP Right Cessation
- 1996-04-10 BR BR9606302A patent/BR9606302A/pt not_active Application Discontinuation
- 1996-04-10 HU HU9603272A patent/HU225463B1/hu not_active IP Right Cessation
- 1996-04-10 PL PL96317647A patent/PL185056B1/pl unknown
- 1996-04-10 NZ NZ304889A patent/NZ304889A/xx not_active IP Right Cessation
- 1996-04-10 MX MX9606217A patent/MX9606217A/es active IP Right Grant
- 1996-04-10 JP JP8530733A patent/JPH10501558A/ja not_active Withdrawn
- 1996-04-10 CN CNB961905913A patent/CN1161122C/zh not_active Expired - Fee Related
- 1996-04-10 EA EA199600105A patent/EA000189B1/ru not_active IP Right Cessation
- 1996-04-10 AU AU52769/96A patent/AU719877B2/en not_active Ceased
- 1996-04-10 CA CA002192438A patent/CA2192438C/en not_active Expired - Fee Related
- 1996-04-10 DE DE69635257T patent/DE69635257D1/de not_active Expired - Lifetime
- 1996-04-10 WO PCT/ES1996/000082 patent/WO1996032113A1/es active IP Right Grant
- 1996-04-10 EP EP96909178A patent/EP0760240B1/en not_active Expired - Lifetime
- 1996-12-11 NO NO19965303A patent/NO313536B1/no not_active IP Right Cessation
-
2000
- 2000-09-01 US US09/654,332 patent/US6290994B1/en not_active Expired - Lifetime
-
2007
- 2007-09-25 JP JP2007247938A patent/JP2008056681A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH10501558A (ja) | 1998-02-10 |
PL185056B1 (pl) | 2003-02-28 |
ATE306268T1 (de) | 2005-10-15 |
EP0760240A1 (en) | 1997-03-05 |
CN1155842A (zh) | 1997-07-30 |
CA2192438A1 (en) | 1996-10-17 |
EP0760240B1 (en) | 2005-10-12 |
HU225463B1 (en) | 2006-12-28 |
US6290994B1 (en) | 2001-09-18 |
HUP9603272A3 (en) | 2000-07-28 |
MX9606217A (es) | 1998-03-31 |
CA2192438C (en) | 2009-03-17 |
AU5276996A (en) | 1996-10-30 |
EA000189B1 (ru) | 1998-12-24 |
NZ304889A (en) | 1999-02-25 |
WO1996032113A1 (es) | 1996-10-17 |
AU719877B2 (en) | 2000-05-18 |
NO313536B1 (no) | 2002-10-21 |
NO965303D0 (no) | 1996-12-11 |
HUP9603272A2 (hu) | 2000-04-28 |
NO965303L (no) | 1997-01-28 |
BR9606302A (pt) | 1997-11-18 |
JP2008056681A (ja) | 2008-03-13 |
PL317647A1 (en) | 1997-04-14 |
EA199600105A1 (ru) | 1997-09-30 |
CN1161122C (zh) | 2004-08-11 |
DE69635257D1 (de) | 2006-02-23 |
ES2097703A1 (es) | 1997-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2097703B1 (es) | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. | |
ES2173420T3 (es) | Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion. | |
ES2176432T3 (es) | Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector. | |
BRPI0411986A (pt) | forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica | |
BR9916887A (pt) | Uso de derivados de pirimidina | |
Bracco et al. | Lateralization of choline acetyltransferase (ChAT) activity in fetus and adult human brain | |
Whelpton et al. | Bioavailability of oral physostigmine. | |
Ropert et al. | Fluoxetine versus clomipramine in major depressive disorders. | |
Harbison | Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease | |
BR0313224A (pt) | Composição farmacêutica contendo composto para terapia da disfunção sexual para ser administrada de modo oral que proporciona rápido inìcio de seus efeitos farmacológicos | |
Meco et al. | Risperidone in Huntington's disease. | |
Holsboer et al. | Combined estradiol and vitamin B₆ treatment in women with major depression. | |
Cremata Jr et al. | Clinical and biochemical effects of fenclonine: A serotonin depletor. | |
Garner | Sodium nitroprusside treatment in patients with acute strokes | |
USD220220S (en) | Nose unit for high speed railroad train | |
USD230970S (en) | Passenger vehicle | |
Maine et al. | Geriatric drug testing—who will volunteer? A descriptive survey. | |
ES2107400T1 (es) | Nueva utilizacion terapeutica de superoxidos dismutasas. | |
王小马 et al. | THE EFFECT OF ACUPUNCTURE IN 90 CASES OF SEQUELAE OF BRAIN CONCUSSION | |
USD123226S (en) | Front car of a railway train | |
USD224657S (en) | Combined golf ball marker and holder | |
USD223791S (en) | Ski-shoe | |
RU96108458A (ru) | Способ лечения заболеваний центральной нервной системы | |
USD211092S (en) | Intercom unit | |
Shimizu et al. | Effects of ozone administration on cerebral and hepatic tissue metabolism in hemorrhagic shock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC2A | Transfer of patent |
Owner name: DECOX, S.A. |
|
EC2A | Search report published |
Date of ref document: 19970401 Kind code of ref document: A1 Effective date: 19970401 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20150826 |